One MedImmune Way
23 articles with Viela Bio
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
Viela Bio, a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, announced it will host a webcast and conference call on Wednesday, August 12, 2020 at 5:00 p.m. ET to discuss its second quarter 2020 financial results and program highlights.
The FDA approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive. About 80% of all NMOSD patients test positive for anti-AQP4 antibodies.
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive
The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period.
Viela Bio announced it will host a webcast and conference call on Wednesday, May 13, 2020 at 5:00 p.m. ET to discuss its first quarter 2020 financial results and program highlights.
Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
Viela Bio announced it will host a webcast and conference call on Wednesday, March 25, 2020 at 5:00 p.m. ET to discuss its fourth quarter and full year 2019 operating and financial results.
Each year, BioSpace evaluates biotech startups for the last year and applies an algorithm that includes funding, collaboration, the state of their pipeline and editorial awards for innovation.
Viela Bio reported financial results and provided program highlights for the third quarter ended September 30, 2019.
Viela Bio Announces Data Presentations at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Viela Bio announced that data from the N-MOmentum trial—the largest global, placebo-controlled study conducted in patients with neuromyelitis optica spectrum disorder—have been selected for an oral plenary session presentation as well as poster presentations at the upcoming 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder
Viela Bio announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder.
Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder
Viela Bio announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for inebilizumab, an investigational anti-CD19 monoclonal antibody, for the treatment of patients with neuromyelitis optica spectrum disorder — a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.
Mr. Nolet brings more than 38 years of financial leadership experience in the Life Sciences industry.
7/3/2019Biotech and pharma companies strengthen their executive leadership and board positions.
Viela Bio announced the appointment of Mitchell Chan as Chief Financial Officer, effective July 1.
Funding to support regulatory filing and pre-commercial planning for lead product candidate, inebilizumab, and to advance development of additional clinical candidates targeting autoimmune and inflammatory diseases
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China
Viela Bio, Inc. and Hansoh Pharmaceutical Group Company Limited announced a collaboration focused on development and commercialization of inebilizumab – Viela’s humanized anti-CD19 monoclonal antibody – in China for neuromyelitis optica spectrum disorder, as well as other potential inflammation/autoimmune and hematologic malignancy indications.
Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting
Company to hold investor event on May 9th
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
Designation based on positive primary analysis of pivotal study, N-MOmentum
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.